1005 studies found for:    "age-related macular degeneration"
Show Display Options
Rank Status Study
1 Active, not recruiting Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Conditions: Age-Related Macular Degeneration;   Wet Age-Related Macular Degeneration;   Macular Degeneration;   Eye Diseases;   Retinal Diseases
Intervention: Device: IRay
2 Completed Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Conditions: Age-related Macular Degeneration;   Pigment Epithelial Detachment;   Neovascular Macular Degeneration;   Wet Macular Degeneration
Intervention: Drug: ranibizumab
3 Completed
Has Results
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Age-related Macular Degeneration;   Neovascular Macular Degeneration
Intervention: Drug: Pegaptanib
4 Recruiting An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Wet Macular Degeneration;   Macular Degeneration;   Eye Diseases;   Retinal Diseases
Intervention: Device: IRay
5 Terminated
Has Results
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
Conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration;   Age-related Macular Degeneration
Interventions: Drug: Everolimus;   Drug: Ranibizumab
6 Withdrawn Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
Conditions: Wet Age-related Macular Degeneration;   Age-related Macular Degeneration;   AMD;   Wet AMD;   Macular Degeneration
Intervention: Device: IRay
7 Unknown  INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
Conditions: AMD;   Wet AMD;   Age-Related Macular Degeneration;   Wet Age-Related Macular Degeneration;   Macular Degeneration;   Eye Diseases;   Retinal Diseases
Intervention: Device: IRay
8 Active, not recruiting Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Macular Degeneration
Interventions: Drug: Intravitreal Aflibercept Injection More;   Drug: Intravitreal Aflibercept Injection Less
9 Active, not recruiting Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
Conditions: Age Related Macular Degeneration;   Macular Degeneration;   AMD
Intervention: Drug: HuCNS-SC cells
10 Unknown  HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
Conditions: Wet Macular Degeneration;   Macular Degeneration;   Pigment Epithelium of Eye;   Retinal Detachment
Intervention: Drug: ranibizumab
11 Terminated A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Conditions: Age Related Macular Degeneration;   Choroidal Neovascular Membrane;   Subfoveal Neovascular Age-Related Macular Degeneration;   Macular Degeneration;   Wet Age-Related Macular Degeneration
Intervention: Drug: Ranibizumab
12 Completed Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD);   Exudative Macular Degeneration
Interventions: Drug: LFG316;   Drug: Placebo
13 Completed Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Other: Proton beam irradiation and ranibizumab
14 Completed Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
15 Not yet recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
16 Completed
Has Results
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
17 Unknown  Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Pegaptanib (Macugen®)
18 Recruiting Neovascular Age-related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration
Intervention:
19 Completed Bevacizumab for Neovascular Age-related Macular Degeneration
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: Bevacizumab 1;   Drug: Bevacizumab
20 Completed
Has Results
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Condition: Age-related Macular Degeneration
Intervention: Other: no intervention

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years